当前位置: 首页 >> 检索结果
321. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.
作者: Christian Lodberg Hvas.;Simon Mark Dahl Jørgensen.;Søren Peter Jørgensen.;Merete Storgaard.;Lars Lemming.;Mette Mejlby Hansen.;Christian Erikstrup.;Jens Frederik Dahlerup.
来源: Gastroenterology. 2019年156卷5期1324-1332.e3页
Fecal microbiota transplantation (FMT) is recommended for treatment of recurrent Clostridium difficile infection (rCDI). We performed a single-center randomized trial to compare the effects of FMT with those of fidaxomicin and vancomycin.
322. An Interactive Web-Based Educational Tool Improves Detection and Delineation of Barrett's Esophagus-Related Neoplasia.
作者: Jacques J G H M Bergman.;A Jeroen de Groof.;O Pech.;K Ragunath.;D Armstrong.;N Mostafavi.;L Lundell.;J Dent.;M Vieth.;G N Tytgat.;P Sharma.; .
来源: Gastroenterology. 2019年156卷5期1299-1308.e3页
Endoscopic detection of early Barrett's esophagus-related neoplasia (BORN) is a challenge. We aimed to develop a web-based teaching tool for improving detection and delineation of BORN.
323. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition.
作者: Vaios Svolos.;Richard Hansen.;Ben Nichols.;Christopher Quince.;Umer Z Ijaz.;Rodanthi T Papadopoulou.;Christine A Edwards.;David Watson.;Adel Alghamdi.;Asker Brejnrod.;Cecilia Ansalone.;Hazel Duncan.;Lisa Gervais.;Rachel Tayler.;Jonathan Salmond.;Daniele Bolognini.;Robert Klopfleisch.;Daniel R Gaya.;Simon Milling.;Richard K Russell.;Konstantinos Gerasimidis.
来源: Gastroenterology. 2019年156卷5期1354-1367.e6页
Exclusive enteral nutrition (EEN) is the only established dietary treatment for Crohn's disease (CD), but its acceptability is limited. There is a need for novel dietary treatments for CD.
324. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis.
作者: Sudarshan Paramsothy.;Shaun Nielsen.;Michael A Kamm.;Nandan P Deshpande.;Jeremiah J Faith.;Jose C Clemente.;Ramesh Paramsothy.;Alissa J Walsh.;Johan van den Bogaerde.;Douglas Samuel.;Rupert W L Leong.;Susan Connor.;Watson Ng.;Enmoore Lin.;Thomas J Borody.;Marc R Wilkins.;Jean-Frederic Colombel.;Hazel M Mitchell.;Nadeem O Kaakoush.
来源: Gastroenterology. 2019年156卷5期1440-1454.e2页
Fecal microbiota transplantation (FMT) can induce remission in patients with ulcerative colitis (UC). In a randomized controlled trial of FMT in patients with active UC, we aimed to identify bacterial taxonomic and functional factors associated with response to therapy.
325. Risk of Postpolypectomy Bleeding With Uninterrupted Clopidogrel Therapy in an Industry-Independent, Double-Blind, Randomized Trial.
作者: Francis K L Chan.;Moe H Kyaw.;John C Hsiang.;Bing Yee Suen.;Ka Man Kee.;Yee Kit Tse.;Jessica Y L Ching.;Pui Kuan Cheong.;Daphne Ng.;Kelvin Lam.;Angeline Lo.;Vivian Lee.;Siew C Ng.
来源: Gastroenterology. 2019年156卷4期918-925.e1页
Guidelines recommend withholding clopidogrel 7 days before polypectomy to decrease bleeding risk, but these were written based on limited evidence. We investigated whether uninterrupted clopidogrel therapy increases the risk of delayed postpolypectomy bleeding in patients undergoing colonoscopy.
326. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.
作者: William J Sandborn.;Marcoli Cyrille.;Mark Berner Hansen.;Brian G Feagan.;Edward V Loftus.;Gerhard Rogler.;Severine Vermeire.;Martha L Cruz.;Jun Yang.;Michael J Boedigheimer.;Lubna Abuqayyas.;Christine M Evangelista.;Barbara A Sullivan.;Walter Reinisch.
来源: Gastroenterology. 2019年156卷4期946-957.e18页
The α4β7 integrin is a validated target in inflammatory bowel disease. This randomized, phase 2b, placebo-controlled, double-blind study evaluated the efficacy and safety of the anti-α4β7 antibody abrilumab in patients with moderate-to-severe ulcerative colitis despite treatment with conventional therapies.
327. Acceptance and Commitment Therapy Reduces Psychological Stress in Patients With Inflammatory Bowel Diseases.
作者: Brona Wynne.;Louise McHugh.;Wei Gao.;Denise Keegan.;Kathryn Byrne.;Catherine Rowan.;Karen Hartery.;Clemens Kirschbaum.;Glen Doherty.;Garret Cullen.;Barbara Dooley.;Hugh E Mulcahy.
来源: Gastroenterology. 2019年156卷4期935-945.e1页
Patients with Crohn's disease or ulcerative colitis have relatively high levels of stress and psychological dysfunction. Acceptance and commitment therapy (ACT) is a psychological intervention that comprises acceptance and mindfulness procedures, along with commitment and behavior change strategies, to increase psychological flexibility and reduce stress. We performed a randomized controlled trial to investigate the effect of ACT on stress in patients with inflammatory bowel diseases (IBD).
328. An Endoscopic Transluminal Approach, Compared With Minimally Invasive Surgery, Reduces Complications and Costs for Patients With Necrotizing Pancreatitis.
作者: Ji Young Bang.;Juan Pablo Arnoletti.;Bronte A Holt.;Bryce Sutton.;Muhammad K Hasan.;Udayakumar Navaneethan.;Nicholas Feranec.;C Mel Wilcox.;Benjamin Tharian.;Robert H Hawes.;Shyam Varadarajulu.
来源: Gastroenterology. 2019年156卷4期1027-1040.e3页
Infected necrotizing pancreatitis is a highly morbid disease with poor outcomes. Intervention strategies have progressed from open necrosectomy to minimally invasive approaches. We compared outcomes of minimally invasive surgery vs endoscopic approaches for patients with infected necrotizing pancreatitis.
329. Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women.
作者: Karen E Hansen.;Jeri W Nieves.;Sai Nudurupati.;David C Metz.;Maria Claudia Perez.
来源: Gastroenterology. 2019年156卷4期926-934.e6页
Epidemiological studies have associated proton pump inhibitor (PPI) therapy with osteoporotic fractures, but it is not clear if PPIs directly cause osteoporosis. We evaluated the effect of dexlansoprazole and esomeprazole on bone turnover, bone mineral density (BMD), true fractional calcium absorption (TFCA), serum and urine levels of minerals, and levels of parathyroid hormone (PTH) in healthy postmenopausal women.
330. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
作者: Ikuo Hirano.;Margaret H Collins.;Yehudith Assouline-Dayan.;Larry Evans.;Sandeep Gupta.;Alain M Schoepfer.;Alex Straumann.;Ekaterina Safroneeva.;Michael Grimm.;Heather Smith.;Cindy-Ann Tompkins.;Amy Woo.;Robert Peach.;Paul Frohna.;Sheila Gujrathi.;Darryl N Penenberg.;Caiyan Li.;Gregory J Opiteck.;Allan Olson.;Richard Aranda.;Marc E Rothenberg.;Evan S Dellon.; .
来源: Gastroenterology. 2019年156卷3期592-603.e10页
Eosinophilic esophagitis (EoE) is a chronic, esophageal, type 2 inflammatory response associated with increased serum levels of interleukin 13 (IL13), which might contribute to its pathogenesis. RPC4046, a recombinant humanized monoclonal antibody against IL13, prevents its binding to the receptor subunits IL13RA1 and IL13RA2. We performed a phase 2 trial to evaluate the efficacy and safety of RPC4046 in patients with EoE.
331. Superiority of Step-up Approach vs Open Necrosectomy in Long-term Follow-up of Patients With Necrotizing Pancreatitis.
作者: Robbert A Hollemans.;Olaf J Bakker.;Marja A Boermeester.;Thomas L Bollen.;Koop Bosscha.;Marco J Bruno.;Erik Buskens.;Cornelis H Dejong.;Peter van Duijvendijk.;Casper H van Eijck.;Paul Fockens.;Harry van Goor.;Wilhelmina M van Grevenstein.;Erwin van der Harst.;Joos Heisterkamp.;Eric J Hesselink.;Sijbrand Hofker.;Alexander P Houdijk.;Tom Karsten.;Philip M Kruyt.;Cornelis J van Laarhoven.;Johan S Laméris.;Maarten S van Leeuwen.;Eric R Manusama.;I Quintus Molenaar.;Vincent B Nieuwenhuijs.;Bert van Ramshorst.;Daphne Roos.;Camiel Rosman.;Alexander F Schaapherder.;George P van der Schelling.;Robin Timmer.;Robert C Verdonk.;Ralph J de Wit.;Hein G Gooszen.;Marc G Besselink.;Hjalmar C van Santvoort.; .
来源: Gastroenterology. 2019年156卷4期1016-1026页
In a 2010 randomized trial (the PANTER trial), a surgical step-up approach for infected necrotizing pancreatitis was found to reduce the composite endpoint of death or major complications compared with open necrosectomy; 35% of patients were successfully treated with simple catheter drainage only. There is concern, however, that minimally invasive treatment increases the need for reinterventions for residual peripancreatic necrotic collections and other complications during the long term. We therefore performed a long-term follow-up study.
332. Thermal Ablation of Mucosal Defect Margins Reduces Adenoma Recurrence After Colonic Endoscopic Mucosal Resection.
作者: Amir Klein.;David J Tate.;Vanoo Jayasekeran.;Luke Hourigan.;Rajvinder Singh.;Gregor Brown.;Farzan F Bahin.;Nicholas Burgess.;Stephen J Williams.;Eric Lee.;Mayenaaz Sidhu.;Karen Byth.;Michael J Bourke.
来源: Gastroenterology. 2019年156卷3期604-613.e3页
Colorectal cancer (CRC) can be prevented by colonoscopy and polypectomy. Endoscopic mucosal resection (EMR) is performed to remove large laterally spreading colonic lesions that have a high risk of progression to CRC. Endoscopically invisible micro-adenomas at the margins of the EMR site might contribute to adenoma recurrence, which occurs in 15% to 30% of patients who undergo surveillance. We aimed to determine the efficacy of adjuvant thermal ablation of the EMR mucosal defect margin in reducing polyp recurrence.
333. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
作者: Rohit Loomba.;Arun J Sanyal.;Kris V Kowdley.;Norah Terrault.;Naga P Chalasani.;Manal F Abdelmalek.;Arthur J McCullough.;Reshma Shringarpure.;Beatrice Ferguson.;Lois Lee.;Jianfen Chen.;Alexander Liberman.;David Shapiro.;Brent A Neuschwander-Tetri.
来源: Gastroenterology. 2019年156卷1期88-95.e5页
Nonalcoholic steatohepatitis (NASH) is a leading cause of liver transplantation, and many trials are underway to evaluate potential therapies. The farnesoid X receptor ligand obeticholic acid in the NASH treatment trial evaluated the effects of obeticholic acid vs placebo on histologic response (defined as decrease in nonalcoholic fatty liver disease activity score [NAS] by ≥2, with no worsening of fibrosis); 45% of patients had a histologic response to obeticholic acid (25 mg), and 21% had a response to placebo (P < .01). We performed a secondary analysis of data from this trial to identify clinical parameters associated with a histologic response.
334. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.
作者: Stephan Miehlke.;Daniela Aust.;Emese Mihaly.;Peter Armerding.;Günther Böhm.;Ole Bonderup.;Fernando Fernández-Bañares.;Juozas Kupcinskas.;Lars Kristian Munck.;Kai-Uwe Rehbehn.;Tanju Nacak.;Roland Greinwald.;Andreas Münch.; .
来源: Gastroenterology. 2018年155卷6期1795-1804.e3页
Lymphocytic colitis is a common cause of chronic, nonbloody diarrhea. However, the effects of treatment are unclear and randomized placebo-controlled trials were requested in a Cochrane review. We performed a randomized, placebo-controlled, multicenter study to evaluate budesonide and mesalazine as induction therapy for lymphocytic colitis.
335. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
作者: Shuzhen Wang.;Xin Zhang.;Tao Han.;Wen Xie.;Yonggang Li.;Hong Ma.;Roman Liebe.;Honglei Weng.;Hui-Guo Ding.
来源: BMC Gastroenterol. 2018年18卷1期137页
Although tolvaptan treatment improves hyponatremia, only few studies have investigated whether tolvaptan actually benefits the survival of cirrhotic patients. This study evaluated the impact of tolvaptan on six-month survival of decompensated cirrhotic patients with and without hyponatremia.
336. Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial.
作者: Jean Damascene Kabakambira.;Celestin Hategeka.;Cameron Page.;Cyprien Ntirenganya.;Vincent Dusabejambo.;Jules Ndoli.;Francois Ngabonziza.;DeVon Hale.;Claude Bayingana.;Tim Walker.
来源: BMC Gastroenterol. 2018年18卷1期134页
Successful H. pylori treatment requires the knowledge of local antimicrobial resistance. Data on the efficacy of H. pylori eradication regimens available in sub-Saharan Africa are scant, hence the optimal treatment is unknown. Our goals were to determine the efficacy of available regimens in Rwanda as well as evaluate the effect of treatment on health-related quality of life (HRQoL) in patients undergoing esophagogastroduodenoscopy.
337. Mortality From Postscreening (Interval) Colorectal Cancers Is Comparable to That From Cancer in Unscreened Patients-A Randomized Sigmoidoscopy Trial.
作者: Henriette C Jodal.;Magnus Løberg.;Øyvind Holme.;Hans-Olov Adami.;Michael Bretthauer.;Louise Emilsson.;David F Ransohoff.;Geir Hoff.;Mette Kalager.
来源: Gastroenterology. 2018年155卷6期1787-1794.e3页
Endoscopic screening for colorectal cancer (CRC) is performed at longer time intervals than the fecal occult blood test or screenings for breast or prostate cancer. This causes concerns about interval cancers, which have been proposed to progress more rapidly. We compared outcomes of patients with interval CRCs after sigmoidoscopy screening vs outcomes of patients with CRC who had not been screened.
338. The influence of various distractions prior to upper gastrointestinal endoscopy: a prospective randomized controlled study.
作者: Masahiro Sogabe.;Toshiya Okahisa.;Yuka Adachi.;Masanori Takehara.;Shinichi Hamada.;Jun Okazaki.;Yasuteru Fujino.;Akira Fukuya.;Kaizo Kagemoto.;Akihiro Hirao.;Koichi Okamoto.;Masahiko Nakasono.;Tetsuji Takayama.
来源: BMC Gastroenterol. 2018年18卷1期132页
Although many patients still have anxiety about upper gastrointestinal (GI) endoscopy, there have been few reports on the influence of distractions for a person who is going to undergo upper GI endoscopy soon. This study was a prospective randomized controlled study investigating the influence of distractions, such as auditive and visual distractions using subjective and objective assessments including autonomic nervous function prior to upper GI endoscopy.
339. Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
作者: Richard Moreau.;Laure Elkrief.;Christophe Bureau.;Jean-Marc Perarnau.;Thierry Thévenot.;Faouzi Saliba.;Alexandre Louvet.;Pierre Nahon.;Adrien Lannes.;Rodolphe Anty.;Sophie Hillaire.;Blandine Pasquet.;Violaine Ozenne.;Marika Rudler.;Isabelle Ollivier-Hourmand.;Marie Angèle Robic.;Louis d'Alteroche.;Vincent Di Martino.;Marie-Pierre Ripault.;Arnaud Pauwels.;Jean-Didier Grangé.;Nicolas Carbonell.;Jean-Pierre Bronowicki.;Audrey Payancé.;Pierre-Emmanuel Rautou.;Dominique Valla.;Nathalie Gault.;Didier Lebrec.; .
来源: Gastroenterology. 2018年155卷6期1816-1827.e9页
There is debate over the effects of long-term oral fluoroquinolone therapy in patients with advanced cirrhosis. We performed a randomized controlled trial to evaluate the effects of long-term treatment with the fluoroquinolone norfloxacin on survival of patients with cirrhosis.
340. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.
作者: Elliot S Friedman.;Yun Li.;Ting-Chin David Shen.;Jack Jiang.;Lillian Chau.;Luciano Adorini.;Farah Babakhani.;Jeffrey Edwards.;David Shapiro.;Chunyu Zhao.;Rotonya M Carr.;Kyle Bittinger.;Hongzhe Li.;Gary D Wu.
来源: Gastroenterology. 2018年155卷6期1741-1752.e5页
Intestinal bacteria can modify the composition of bile acids and bile acids, which are regulated by the farnesoid X receptor, affect the survival and growth of gut bacteria. We studied the effects of obeticholic acid (OCA), a bile acid analogue and farnesoid X receptor agonist, on the intestinal microbiomes of humans and mice.
|